Cathay Biotech Bilan de santé

Santé financière contrôle des critères 5/6

Cathay Biotech possède un total de capitaux propres de CN¥15.0B et une dette totale de CN¥1.3B, ce qui porte son ratio d'endettement à 8.7%. Son actif total et son passif total sont CN¥18.3B et de CN¥3.3B. L'EBIT de Cathay Biotech est CN¥316.0M ce qui fait que son ratio de couverture des intérêts -2.4. Elle dispose de liquidités et de placements à court terme de CN¥4.6B.

Informations clés

8.7%

Ratio d'endettement

CN¥1.30b

Dette

Ratio de couverture des intérêts	-2.4x
Argent liquide	CN¥4.64b
Fonds propres	CN¥14.99b
Total du passif	CN¥3.34b
Total des actifs	CN¥18.33b

Mises à jour récentes de la santé financière

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Sep 29

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28

Recent updates

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Oct 22

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Jun 19

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

May 28

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

May 07

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

May 06

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 688065 ( CN¥6.8B ) dépassent ses passifs à court terme ( CN¥2.4B ).

Passif à long terme: Les actifs à court terme de 688065 ( CN¥6.8B ) dépassent ses passifs à long terme ( CN¥966.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 688065 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 688065 est passé de 6% à 8.7% au cours des 5 dernières années.

Couverture de la dette: La dette de 688065 est bien couverte par le flux de trésorerie opérationnel ( 55.1% ).

Couverture des intérêts: 688065 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Cathay Biotech Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)

Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.

What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You

Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024

Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly

Investor sentiment improves as stock rises 23%

Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)

Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024

There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital

Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024

Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet

What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You

We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 21%

New major risk - Revenue and earnings growth

Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)

Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.

Price target increased by 8.3% to CN¥67.18

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)

Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023

Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group Limited

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)

Less than half of directors are independent

Cathay Biotech Inc. announced that it has received $28 million in funding from Eight Roads Ventures, Sequoia China Investment Management LLP, Source Code Capital, Bits x Bites

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 3Q 2021)

Price target increased to CN¥91.82

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.34 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥1.46 (vs CN¥1.18 in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.23 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.32 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.18 (vs CN¥1.32 in FY 2019)

Cathay Biotech Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥82.67

New 90-day low: CN¥88.56

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines